Overview

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

The primary objective is to evaluate the efficacy of once daily (QD) subcutaneous (SC) injections of Semuloparin sodium (AVE5026) versus placebo for 3 additional weeks following an initial 7 to 10-day venous thromboprophylaxis with open-label AVE5026 in patients having undergone hip fracture surgery. The secondary objective is to evaluate the safety of extended AVE5026 administration.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Heparin, Low-Molecular-Weight
Semuloparin